You are here

  • Home
  • Archive
  • Volume 9, Issue 7
  • First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Citation Tools

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
D'Angelo SP, Lebbé C, Mortier L, et al
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Journal for ImmunoTherapy of Cancer 2021;9:e002646. doi: 10.1136/jitc-2021-002646